<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111211</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2019/16</org_study_id>
    <nct_id>NCT04111211</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits</brief_title>
  <acronym>Memento-Plus</acronym>
  <official_title>Memento-Plus : Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dementia is a clinical syndrome that is the result of distinct underlying pathologies
      including Alzheimer's disease (AD). Despite more than two decades of research on prevention
      and treatment of dementia and aging-related cognitive decline, highly effective preventive
      and therapeutic strategies remain elusive.

      Many features of dementia render it especially challenging. Indeed development of disease
      occurs insidiously over the course of years or decade. In addition, the causes of dementia
      and determinants of its severity are likely multi-factorial.

      To overcome these challenges and better understand the causes and course of AD and related
      disorders, long term follow-up studies of persons at high risk of dementia are required
      including multidimensional and harmonized assessment of risk factors, phenotypes (cognition,
      neuropsychiatric symptoms, physical health, self rated health) and endophenotypes (blood
      markers, genetic markers, neuroimaging markers).

      This project proposes an extension of the follow-up of Memento participants over 5 to 10
      years with of focus on cognitive outcomes and comorbidities.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression to clinical dementia stage according to standardized classifications (DSM-IV for dementia and NINCDS-ADRDA for Alzheimer's disease)</measure>
    <time_frame>Each 12 months from baseline for 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Each 12 months from baseline for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of autonomy based on functional activity assessment</measure>
    <time_frame>Each 12 months from baseline for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cognitive decline based on change in cognitive performances</measure>
    <time_frame>Each 12 months from baseline for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neurovascular and cardiovascular events (Stroke and Coronary events)</measure>
    <time_frame>Each 12 months from baseline for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: EQ-5D (EUROQOL)</measure>
    <time_frame>Each 12 months from baseline for 5 years</time_frame>
    <description>EQ-5D (EUROQOL) questionnaire Subscales: VAS patient's self-rated health (0=worst, 100=best), mobility, self-care, usual activities, pain/discomfort and anxiety/depression (rated as no problems, slight problems, moderate problems, severe problems and extreme problems)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of prodromal AD (Pre-symptomatic dementia)</measure>
    <time_frame>Each 12 months from baseline for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of institutionalization</measure>
    <time_frame>Each 12 months from baseline for 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Individuals at high risk of developing Alzheimer's dementia</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients from French Research Memory Centers and included in Memento cohort
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants aged over 18 year-old

          -  Being included in Memento cohort

          -  Affiliated person or beneficiary of a social security scheme.

          -  Participants capable of expressing non objection

          -  Non objection expressed by the tutor for participants under tutorship

          -  Non objection expressed by the participant assisted by their guardian for participants
             under guardianship

          -  Non objection expressed by the trusted person (in accordance with art. L1111-6 of Code
             de la Santé Publique) for participants without the capacity to express non-objection
             and who are not under legal protection measure

        Exclusion Criteria:

          -  Expressing opposition to participate in Memento-Plus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geneviève CHENE, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC-1401 EC - ISPED - CHU de Bodeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geneviève CHENE, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>CIC-1401 EC - ISPED - CHU de Bodeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carole DUFOUIL, Director</last_name>
    <role>Study Director</role>
    <affiliation>CIC-1401 EC - ISPED - CHU de Bodeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geneviève CHENE, Prof</last_name>
    <phone>(0)5 57 57 13 92</phone>
    <phone_ext>+33</phone_ext>
    <email>genevieve.chene@u-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carole DUFOUIL, Director</last_name>
    <phone>(0)5 57 57 14 23</phone>
    <phone_ext>+33</phone_ext>
    <email>carole.dufouil@u-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier GODEFROY, Prof</last_name>
      <email>godefroy.olivier@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier GODEFROY, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - CHU Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beatrice GARCIN, MD</last_name>
      <email>beatrice.garcin@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Beatrice GARCIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François TISON, Prof</last_name>
      <email>francois.tison@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>François TISON, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle JALENQUES, Prof</last_name>
      <email>ijalenques@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle JALENQUES, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François SELLAL, MD</last_name>
      <email>francois.sellal@ch-colmar.fr</email>
    </contact>
    <investigator>
      <last_name>François SELLAL, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benoit DELPONT, MD</last_name>
      <email>Benoit.delpont@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Benoit DELPONT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathilde SAUVEE, MD</last_name>
      <email>msauvee@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Mathilde SAUVEE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florence PASQUIER, Prof</last_name>
      <email>florence.pasquier@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Florence PASQUIER, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathieu CECCALDI, Prof</last_name>
      <email>mathieu-pierre.ceccaldi@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu CECCALDI, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Audrey GABELLE, MD</last_name>
      <email>a-gabelle@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Audrey GABELLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Athanase BENETOS, Prof</last_name>
      <email>a.benetos@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Athanase BENETOS, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire BOUTOLEAU-BRETONNIERE, MD</last_name>
      <email>claire.boutoleaubretonniere@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Claire BOUTOLEAU-BRETONNIERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renaud DAVID, MD</last_name>
      <email>david.r@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Renaud DAVID, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital BROCA</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier HANON, Prof</last_name>
      <email>olivier.hanon@brc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier HANON, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ap-Hp La Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno DUBOIS, Prof</last_name>
    </contact>
    <contact_backup>
      <email>bruno.dubois@psl.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Bruno DUBOIS, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Groupe Hospitalier Saint Louis Lariboisière Fernand Widal</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire PAQUET, MD</last_name>
      <email>claire.paquet@inserm.fr</email>
    </contact>
    <investigator>
      <last_name>Claire PAQUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muriel RAINFRAY, Prof</last_name>
      <email>muriel.rainfray@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Muriel RAINFRAY, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc PACCALIN, Prof</last_name>
      <email>Marc.paccalin@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Marc PACCALIN, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David WALLON, MD</last_name>
      <email>David.Wallon@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>David WALLON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle ROUCH, MD</last_name>
      <email>i.rouch@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle ROUCH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric BLANC, MD</last_name>
      <email>frederic.blanc@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric BLANC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérémie PARIENTE, Prof</last_name>
      <email>jeremie.pariente@inserm.fr</email>
    </contact>
    <investigator>
      <last_name>Jérémie PARIENTE, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno VELLAS, Prof</last_name>
      <email>vellas.b@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno VELLAS, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilie BEAUFILS, MD</last_name>
      <email>e.beaufils@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Emilie BEAUFILS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospice Civil de Lyon</name>
      <address>
        <city>Villeurbanne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre KROLAK SALMON, Prof</last_name>
      <email>pierre.krolak-salmon@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre KROLAK SALMON, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>related disorders</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

